To Study the Effect of SC-FOS Prebiotics in Women With Polycystic Ovary Syndrome

Last updated: February 1, 2024
Sponsor: Universidad Autonoma de Chihuahua
Overall Status: Active - Recruiting

Phase

N/A

Condition

Polycystic Ovarian Syndrome

Reproductive Health

Treatment

Placebo Group

Short Chain Fructooligosaccharides

Clinical Study ID

NCT05999097
030C-06/23
  • Ages 18-65
  • Female
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to determine if there is a difference in the clinical characteristics of patients with polycystic ovary syndrome after the administration of SC-FOS in the enteral diet compared to patients with a standard diet.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female sex
  • Age 18 to 65 years
  • Polycystic Ovary Syndrome diagnosed by specialist
  • Useful enteral feeding

Exclusion

Exclusion Criteria:

  • Pregnancy
  • Diabetes mellitus
  • Risk of intestinal perforation

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Placebo Group
Phase:
Study Start date:
December 02, 2024
Estimated Completion Date:
May 30, 2025

Study Description

The protocol will be discussed with the patients and/or relatives of the patients, who will understand the consequences and advantages of the study and will thus sign the consent.

Once informed consent has been obtained, the group to which each patient belongs will be randomly assigned.

Patients will be selected according to the inclusion and exclusion criteria of the population diagnosed with PCOS with useful enteral route for random assignment into two groups, one will be administered short-chain Fructooligosaccharides at a dose of 12 g every 24 hours, another group will be given saline as a placebo to the enteral diet every 24 hours for 10 days. Patients should take the solution on an empty stomach.

Once the type of intervention has been determined, the patient will be given the suspensions corresponding to group 1 or placebo, with vials in which the content cannot be visualized, numbered according to the sheet obtained by the corresponding randomization. The initial evaluation will be completed with all the clinical characteristics to be evaluated.

The patient will be told that every 24 hours he must take 1 suspension on an empty stomach, which will be prepared at a rate of 12 grams of SC-FOS in 15 cc of saline solution for the prebiotic preparation vs 15 cc of saline solution for the placebo group. The solution will be administered enterally for 10 consecutive days at a single dose per day, and a reassessment will be made on the seventh day of the clinical characteristics of the patients, to compare and evaluate the results.

Connect with a study center

  • Hospital Central del Estado de Chihuahua

    Chihuahua, 31000
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.